OPUVIZ

Growth

aflibercept-yszy

Samsung Bioepis
BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Company
Samsung Bioepis
Samsung Bioepis
Korea - Incheon
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers